Combined effects of leukocyte telomere length, p53 polymorphism and human papillomavirus infection on esophageal squamous cell carcinoma in a Han Chinese population

Cancer Epidemiology

Volumn 38, Issue 5, 2014, Pages 569-575

  Yu, Qianqian ^a   Yang, Ju ^a   Liu, Bo ^a   Li, Wen ^a   Hu, Guangyuan ^a   Qiu, Hong ^a   Huang, Liu ^a   Xiong, Huihua ^a   Yuan, Xianglin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Esophageal squamous cell carcinoma; Human papillomavirus 16; P53; Telomere length

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CELL CYCLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENOMIC INSTABILITY; GENOTYPE; HAN CHINESE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN DEGRADATION; PROTEIN POLYMORPHISM; SEROLOGY; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; ESOPHAGUS TUMOR; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; RISK; RISK FACTOR; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHINA; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; RISK; RISK FACTORS; TELOMERE SHORTENING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908113863     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.07.010     Document Type: Article

References (51)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
3. Yeole B.B., Kumar A.V. Population-based survival from cancers having a poor prognosis in Mumbai (Bombay), India. Asian Pac J Cancer Prev 2004, 5(2):175-182.
4. Aghcheli K., Marjani H.A., Nasrollahzadeh D., Islami F., Shakeri R., Sotoudeh M., et al. Prognostic factors for esophageal squamous cell carcinoma - a population-based study in Golestan Province, Iran, a high incidence area. PLoS ONE 2011, 6(7):e22152.
5. Li J., Song Q., Zhou X., Jiang C., Wang D., Wang X., et al. Major cancer mortality and changes in Yanting, 2004-2009: introduction to cancer challenges in a high risk area. Asian Pac J Cancer Prev 2011, 12(2):409-413.
6. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
7. Tran G.D., Sun X.D., Abnet C.C., Fan J.H., Dawsey S.M., Dong Z.W., et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 2005, 113(3):456-463.
8. Zheng Y.L., Hu N., Sun Q., Wang C., Taylor P.R. Telomere attrition in cancer cells and telomere length in tumor stroma cells predict chromosome instability in esophageal squamous cell carcinoma: a genome-wide analysis. Cancer Res 2009, 69(4):1604-1614.
9. Kammori M., Poon S.S., Nakamura K., Izumiyama N., Ishikawa N., Kobayashi M., et al. Squamous cell carcinomas of the esophagus arise from a telomere-shortened epithelial field. Int J Mol Med 2007, 20(6):793-799.
10. Takubo K., Fujita M., Izumiyama N., Nakamura K., Ishikawa N., Poon S.S., et al. Q-FISH analysis of telomere and chromosome instability in the oesophagus with and without squamous cell carcinoma in situ. J Pathol 2010, 221(2):201-209.
11. de Lange T., Shiue L., Myers R.M., Cox D.R., Naylor S.L., Killery A.M., et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990, 10(2):518-527.
12. Cheung A.L., Deng W. Telomere dysfunction, genome instability and cancer. Front Biosci: J Virtual Libr 2008, 13:2075-2090.
13. Wentzensen I.M., Mirabello L., Pfeiffer R.M., Savage S.A. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomark Prev 2011, 20(6):1238-1250.
14. Kammori M., Izumiyama N., Nakamura K., Kurabayashi R., Kashio M., Aida J., et al. Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization. Oncology 2006, 71(5-6):430-436.
15. Artandi S.E., Attardi L.D. Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem Biophys Res Commun 2005, 331(3):881-890.
16. Shay J.W., Wright W.E. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005, 26(5):867-874.
17. Wright W.E., Shay J.W. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 1992, 27(4):383-389.
18. Broccoli D., Young J.W., de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A 1995, 92(20):9082-9086.
19. Walker K.K., Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 1996, 93(26):15335-15340.
20. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33(3):357-365.
21. Ma J., Zhang J., Ning T., Chen Z., Xu C. Association of genetic polymorphisms in MDM2, PTEN and P53 with risk of esophageal squamous cell carcinoma. J Hum Genet 2012, 57(4):261-264.
22. Yang W., Zhang Y., Tian X., Ning T., Ke Y. p53 Codon 72 polymorphism and the risk of esophageal squamous cell carcinoma. Mol Carcinog 2008, 47(2):100-104.
23. Hong Y., Miao X., Zhang X., Ding F., Luo A., Guo Y., et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005, 65(20):9582-9587.
24. Yang J., Liu B., Li W., Xiong H., Qiu H., Fu Q., et al. Association of p53 and MDM2 polymorphisms with risk of human papillomavirus (HPV)-related esophageal squamous cell carcinoma (ESCC). Cancer Epidemiol 2013, 37(5):629-633.
25. Syrjanen K.J. Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas. Arch Geschwulstforsch 1982, 52(4):283-292.
26. Qi Z., Jiang Q., Yang J., Chen X., Wu H., Huang L., et al. Human papillomavirus (HPV) infection and the risk of esophageal squamous cell carcinoma. Dis Esophagus 2013, 26(1):61-67.
27. Li X., Gao C., Yang Y., Zhou F., Li M., Jin Q., et al. Systematic review with meta-analysis: the association between human papillomavirus infection and oesophageal cancer. Aliment Pharmacol Ther 2014, 39(3):270-281.
28. Psyrri A., Boutati E., Karageorgopoulou S. Human papillomavirus in head and neck cancers: biology, prognosis, hope of treatment, and vaccines. Anticancer Drugs 2011, 22(7):586-590.
29. Munger K., Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res 2002, 89(2):213-228.
30. Zhou X., Han S., Wang S., Chen X., Dong J., Shi X., et al. Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical cancer in Chinese women: a case-control analysis. Gynecol Oncol 2009, 114(2):327-331.
31. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998, 393(6682):229-234.
32. Katzenellenbogen R.A., Vliet-Gregg P., Xu M., Galloway D.A. NFX1-123 increases hTERT expression and telomerase activity posttranscriptionally in human papillomavirus type 16 E6 keratinocytes. J Virol 2009, 83(13):6446-6456.
33. Klingelhutz A.J., Foster S.A., McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996, 380(6569):79-82.
34. Liu X., Roberts J., Dakic A., Zhang Y., Schlegel R. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology 2008, 375(2):611-623.
35. Cawthon R.M. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002, 30(10):e47.
36. Zhang Y., Sturgis E.M., Dahlstrom K.R., Wen J., Liu H., Wei Q., et al. Telomere length in peripheral blood lymphocytes contributes to the development of HPV-associated oropharyngeal carcinoma. Cancer Res 2013, 73(19):5996-6003.
37. Wu C., Kraft P., Zhai K., Chang J., Wang Z., Li Y., et al. Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet 2012, 44(10):1090-1097.
38. Risques R.A., Vaughan T.L., Li X., Odze R.D., Blount P.L., Ayub K., et al. Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomark Prev 2007, 16(12):2649-2655.
39. Xing J., Ajani J.A., Chen M., Izzo J., Lin J., Chen Z., et al. Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. Cancer Prev Res 2009, 2(5):459-465.
40. Hsu C.P., Lee L.W., Shai S.E., Chen C.Y. Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus. World J Gastroenterol 2005, 11(44):6941-6947.
41. Zuo J., Wang D.H., Zhang Y.J., Liu L., Liu F.L., Liu W. Expression and mechanism of PinX1 and telomerase activity in the carcinogenesis of esophageal epithelial cells. Oncol Rep 2013, 30(4):1823-1831.
42. Goessel G., Quante M., Hahn W.C., Harada H., Heeg S., Suliman Y., et al. Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci 2005, 102(43):15599-15604.
43. Sashiyama H., Shino Y., Kawamata Y., Tomita Y., Ogawa N., Shimada H., et al. Immortalization of human esophageal keratinocytes by E6 and E7 of human papillomavirus type 16. Int J Oncol 2001, 19(1):97-103.
44. Hardefeldt H.A., Cox M.R., Eslick G.D. Association between human papillomavirus (HPV) and oesophageal squamous cell carcinoma: a meta-analysis. Epidemiol Infect 2014, 142(6):1119-1137.
45. He Z., Xu Z., Hang D., Guo F., Abliz A., Weiss N.S., et al. Anti-HPV-E7 seropositivity and risk of esophageal squamous cell carcinoma in a high-risk population in China. Carcinogenesis 2014, 35(4):816-821.
46. Zhang D.K., Ngan H.Y., Cheng R.Y., Cheung A.N., Liu S.S., Tsao S.W. Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer. Eur J Cancer 1999, 35(1):154-160.
47. Hao X.D., Yang Y., Song X., Zhao X.K., Wang L.D., He J.D., et al. Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer. Oncol Rep 2013, 29(1):226-236.
48. Pal J., Gold J.S., Munshi N.C., Shammas M.A. Biology of telomeres: importance in etiology of esophageal cancer and as therapeutic target. Transl Res 2013, 162(6):364-370.
49. Zhao P., Dai M., Chen W., Li N. Cancer trends in China. Jpn J Clin Oncol 2010, 40(4):281-285.
50. Sjoquist K.M., Burmeister B.H., Smithers B.M., Zalcberg J.R., Simes R.J., Barbour A., et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011, 12(7):681-692.
51. Lao-Sirieix P., Fitzgerald R.C. Screening for oesophageal cancer. Nat Rev Clin Oncol 2012, 9(5):278-287.